Lifevantage (LFVN) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $6.00, +3.45% vs the prior close of $5.80.
- Volume 41.10K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
LFVN jumps 3.4% to $6.00. Closed at $6.00, +3.45% vs the prior close of $5.80. Day range $5.76–$6.12, opened at $5.92.
LFVN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — LFVN jumps 3.4% to $6.00
- Closed at $6.00, +3.45% vs the prior close of $5.80. Day range $5.76–$6.12, opened at $5.92.
- Volume was 41.10K shares, 0.9x its 50-day average of 44.92K.
- Price is -5.0% vs its 50-day average ($6.32) and +1.6% vs its 200-day average ($5.91).
- 52-week range $3.90–$11.71; today's close sits at 27% of that range, 48.8% below the 52-week high.
Oct 14, 2026 — LFVN dips 2.5% to $5.80, a 3-month low, 3 down days in a row
- Closed at $5.80, -2.52% vs the prior close of $5.95. Day range $5.30–$5.94, opened at $5.94.
- Volume was 58.50K shares, 1.3x its 50-day average of 45.11K.
- Price is -8.4% vs its 50-day average ($6.33) and -1.8% vs its 200-day average ($5.91).
- 52-week range $3.90–$11.71; today's close sits at 24% of that range, 50.5% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — LFVN dips 0.5% to $5.95, a 3-month low
- Closed at $5.95, -0.50% vs the prior close of $5.98. Day range $5.93–$6.03, opened at $6.00.
- Volume was 31.30K shares, 0.7x its 50-day average of 45.77K.
- Price is -6.3% vs its 50-day average ($6.35) and +0.7% vs its 200-day average ($5.91).
- 52-week range $3.90–$11.71; today's close sits at 26% of that range, 49.2% below the 52-week high.
Oct 12, 2026 — LFVN dips 0.3% to $5.98, a 3-month low
- Closed at $5.98, -0.33% vs the prior close of $6.00. Day range $5.94–$6.09, opened at $6.00.
- Volume was 22.30K shares, 0.5x its 50-day average of 46.66K — lighter than usual.
- Price is -6.0% vs its 50-day average ($6.36) and +1.2% vs its 200-day average ($5.91).
- 52-week range $3.90–$11.71; today's close sits at 27% of that range, 48.9% below the 52-week high.
Oct 9, 2026 — LFVN ends flat (+0.2%) to $6.00
- Closed at $6.00, +0.17% vs the prior close of $5.99. Day range $5.93–$6.08, opened at $5.93.
- Volume was 23.20K shares, 0.5x its 50-day average of 47.05K — lighter than usual.
- Price is -5.8% vs its 50-day average ($6.37) and +1.5% vs its 200-day average ($5.91).
- 52-week range $3.90–$11.71; today's close sits at 27% of that range, 48.8% below the 52-week high.
Oct 8, 2026 — LFVN ends flat (-0.2%) to $5.99, a 3-month low
- Closed at $5.99, -0.17% vs the prior close of $6.00. Day range $5.94–$6.13, opened at $6.00.
- Volume was 32.40K shares, 0.7x its 50-day average of 47.74K.
- Price is -6.1% vs its 50-day average ($6.38) and +1.3% vs its 200-day average ($5.91).
- 52-week range $3.90–$11.71; today's close sits at 27% of that range, 48.8% below the 52-week high.
Oct 7, 2026 — LFVN dips 0.7% to $6.00, a 3-month low
- Closed at $6.00, -0.66% vs the prior close of $6.04. Day range $5.97–$6.16, opened at $6.00.
- Volume was 25.00K shares, 0.5x its 50-day average of 48.80K — lighter than usual.
- Price is -6.0% vs its 50-day average ($6.38) and +1.5% vs its 200-day average ($5.91).
- 52-week range $3.90–$11.71; today's close sits at 27% of that range, 48.8% below the 52-week high.
Oct 6, 2026 — LFVN ends flat (+0.2%) to $6.04
- Closed at $6.04, +0.17% vs the prior close of $6.03. Day range $5.98–$6.16, opened at $6.03.
- Volume was 30.10K shares, 0.6x its 50-day average of 49.70K.
- Price is -5.5% vs its 50-day average ($6.39) and +2.1% vs its 200-day average ($5.91).
- 52-week range $3.90–$11.71; today's close sits at 27% of that range, 48.4% below the 52-week high.
Oct 5, 2026 — LFVN dips 0.7% to $6.03, a 3-month low, 4 down days in a row
- Closed at $6.03, -0.66% vs the prior close of $6.07. Day range $5.92–$6.18, opened at $6.01.
- Volume was 27.80K shares, 0.6x its 50-day average of 50.29K — lighter than usual.
- Price is -5.8% vs its 50-day average ($6.40) and +1.9% vs its 200-day average ($5.92).
- 52-week range $3.90–$11.71; today's close sits at 27% of that range, 48.5% below the 52-week high.
- That makes 4 straight losses.
- SEC filings that day: 8-K.
Oct 2, 2026 — LFVN dips 2.7% to $6.07, a 3-month low, 3 down days in a row
- Closed at $6.07, -2.72% vs the prior close of $6.24. Day range $5.99–$6.26, opened at $6.24.
- Volume was 48.80K shares, 1.0x its 50-day average of 50.59K.
- Price is -5.3% vs its 50-day average ($6.41) and +2.6% vs its 200-day average ($5.92).
- 52-week range $3.90–$11.71; today's close sits at 28% of that range, 48.2% below the 52-week high.
- That makes 3 straight losses.
LFVN latest news & SEC filings
Every SEC filing by or about LFVN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cunningham Kristen received an award of 32,850 shares on Oct 7, 2026; now holds 152,375
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Aure Carl received an award of 35,749 shares on Oct 7, 2026; now holds 191,784
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Moorehead Terrence received an award of 193,237 shares on Oct 7, 2026; now holds 501,879
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Aure Carl had withheld for taxes 460 shares at $6.24 (≈$2.87K) on Oct 1, 2026; now holds 156,035
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cunningham Kristen had withheld for taxes 637 shares at $6.24 (≈$3.97K) on Oct 1, 2026; now holds 119,525
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
Sep 18, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Sep 18, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Sep 18, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lewis Darwin bought 976 shares at $6.22 (≈$6.07K) on Sep 15, 2026; now holds 138,244
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 27, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 27, 2026 · Form 10-K — Annual report
Annual report (audited full-year financial statements and business review)
Fiscal year ended Jun 30, 2026:
- Revenue: $182.59M (prior year $228.53M) (-20.1% vs Jun 30, 2025)
- Net income: $5.07M (prior year $9.80M) (-48.3% vs Jun 30, 2025)
- Diluted EPS: $0.40 (prior year $0.75) (-46.7% vs Jun 30, 2025)
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 3, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade LFVN
- Last results release: Aug 27, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Feb 4, 2026, Nov 4, 2025. Based on that rhythm, the next report is likely around Nov 26, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.13% (largest 3.4%).
- Liquidity: about 34.06K shares (≈$204.39K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $6.00 vs a range of $3.90–$11.71 (27% of the range).
- Dividends: last ex-dividend date Sep 1, 2026 ($0.05/share); 4 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 6 sales; latest: Darwin Lewis bought 976 shares on Sep 15, 2026.
- Latest filings: 8-K Oct 5, 2026; 8-K Aug 27, 2026; 10-K Aug 27, 2026.
- Share count: 12.53M shares outstanding (Aug 26, 2026), -1.3% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
LFVN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 5.92 | 6.12 | 5.76 | 6.00 | 41.10K |
| Oct 14, 2026 | 5.94 | 5.94 | 5.30 | 5.80 | 58.50K |
| Oct 13, 2026 | 6.00 | 6.03 | 5.93 | 5.95 | 31.30K |
| Oct 12, 2026 | 6.00 | 6.09 | 5.94 | 5.98 | 22.30K |
| Oct 9, 2026 | 5.93 | 6.08 | 5.93 | 6.00 | 23.20K |
| Oct 8, 2026 | 6.00 | 6.13 | 5.94 | 5.99 | 32.40K |
| Oct 7, 2026 | 6.00 | 6.16 | 5.97 | 6.00 | 25.00K |
| Oct 6, 2026 | 6.03 | 6.16 | 5.98 | 6.04 | 30.10K |
| Oct 5, 2026 | 6.01 | 6.18 | 5.92 | 6.03 | 27.80K |
| Oct 2, 2026 | 6.24 | 6.26 | 5.99 | 6.07 | 48.80K |
| Oct 1, 2026 | 6.31 | 6.40 | 6.12 | 6.24 | 36.10K |
| Sep 30, 2026 | 6.32 | 6.34 | 6.21 | 6.30 | 18.30K |
| Sep 29, 2026 | 6.21 | 6.40 | 6.13 | 6.32 | 20.30K |
| Sep 28, 2026 | 6.26 | 6.36 | 6.17 | 6.19 | 32.20K |
| Sep 25, 2026 | 6.29 | 6.42 | 6.25 | 6.26 | 10.30K |
| Sep 24, 2026 | 6.20 | 6.29 | 6.11 | 6.29 | 24.40K |
| Sep 23, 2026 | 6.12 | 6.20 | 6.00 | 6.20 | 75.90K |
| Sep 22, 2026 | 6.16 | 6.32 | 6.15 | 6.22 | 38.10K |
| Sep 21, 2026 | 6.31 | 6.40 | 6.16 | 6.22 | 34.20K |
| Sep 18, 2026 | 6.31 | 6.54 | 6.14 | 6.35 | 51.00K |
About Lifevantage
Lifevantage (LFVN) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in LEHI, UT. Fiscal year ends December 31. SEC CIK 849146.
LFVN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Rajendran Anbalagan | Director | Nov 10, 2025 |
| Michael A Beindorff | Director | Jun 5, 2026 |
| Judd Dayton | Director | Mar 2, 2026 |
| Steven R Fife | President and CEO | Apr 3, 2026 |
| Raymond B Greer | Director | Nov 10, 2025 |
| Cynthia Latham | Director | Nov 10, 2025 |
| Darwin Lewis | Director | Sep 17, 2026 |
| Terrence Moorehead | President and CEO | Aug 10, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Carl Aure | Chief Financial Officer | Sep 14, 2026 |
| Julie Boyster | Chief Marketing Officer | Oct 3, 2025 |
| Kristen Cunningham | Chief Sales Officer | Sep 14, 2026 |
| Steven R Fife | President and CEO | Apr 3, 2026 |
| Terrence Moorehead | President and CEO | Aug 10, 2026 |
| Alissa Neufeld | General Counsel | Jul 6, 2026 |
| Todd Thompson | Chief Information Officer | Dec 29, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | Darwin Lewis | Buy | 976 | $6.22 |
| Sep 14, 2026 | Kristen Cunningham | Sale | 8,901 | $6.18 |
| Sep 11, 2026 | Kristen Cunningham | Sale | 100 | $6.41 |
| Jun 15, 2026 | Darwin Lewis | Buy | 705 | $8.60 |
| Jun 3, 2026 | Michael A Beindorff | Sale | 10,000 | $8.55 |
| Mar 16, 2026 | Darwin Lewis | Buy | 1,055 | $5.23 |
| Mar 2, 2026 | Judd Dayton | Buy | 10,500 | $4.53 |
| Feb 27, 2026 | Judd Dayton | Buy | 18,097 | $4.63 |
| Feb 26, 2026 | Judd Dayton | Buy | 4,600 | $4.58 |
| Feb 9, 2026 | Darwin Lewis | Buy | 3,955 | $5.22 |
| Dec 15, 2025 | Darwin Lewis | Buy | 805 | $6.54 |
| Nov 19, 2025 | Michael A Beindorff | Sale | 12,607 | $6.42 |
| Nov 7, 2025 | Michael A Beindorff | Sale | 35,000 | $6.92 |
| Nov 7, 2025 | Michael A Beindorff | Sale | 1,000 | $7.33 |
LFVN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Jun 30, 2026 | $182.59M | $5.07M | 0.40 | $10.24M |
| Jun 30, 2025 | $228.53M | $9.80M | 0.75 | $11.88M |
| Jun 30, 2024 | $200.16M | $2.94M | 0.23 | $12.20M |
| Jun 30, 2023 | $213.40M | $2.54M | 0.20 | $6.83M |
| Jun 30, 2022 | $206.36M | $3.12M | 0.24 | $7.96M |
Latest balance sheet: total assets $62.11M, total liabilities $28.52M, cash $20.20M (as of Jun 30, 2026).
LFVN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 27, 2026 | 8-K Item 2.02 (results) | $6.45 |
| May 6, 2026 | 8-K Item 2.02 (results) | $6.00 |
| Feb 4, 2026 | 8-K Item 2.02 (results) | $5.55 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $7.00 |
| Sep 4, 2025 | 8-K Item 2.02 (results) | $13.46 |
| May 6, 2025 | 8-K Item 2.02 (results) | $11.97 |
| Feb 5, 2025 | 8-K Item 2.02 (results) | $22.74 |
| Oct 29, 2024 | 8-K Item 2.02 (results) | $12.98 |
| Aug 28, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
| Jan 30, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on LFVN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.